Bone sarcomas in the immunotherapy era-Reference-Cited by-同舟云学术

Bone sarcomas in the immunotherapy era

Published:2020-02-18 Issue:9 Volume:178 Page:1955-1972
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:Br J Pharmacol

Author:

Heymann Marie‐Françoise¹²³,Schiavone Kristina¹²,Heymann Dominique¹²³

Affiliation:

1. Université de Nantes, INSERM, CRCINA Institut de Cancérologie de l'Ouest Saint‐Herblain France

2. “Tumor Heterogeneity and Precision Medicine” Institut de Cancérologie de l'Ouest Saint Herblain France

3. INSERM, European Associated Laboratory “Sarcoma Research Unit”, Department of Oncology and Metabolism, Medical School University of Sheffield Sheffield UK

Publisher

Wiley

Subject

Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bph.14999

Reference134 articles.

1. Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

2. Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression

3. The concise guide to pharmacology 2019/20: Catalytic receptors;Alexander S. P. H.;British Journal of Pharmacology,2019

4. Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production

5. Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomaterials‐Boosted Immunotherapy for Osteosarcoma;Advanced Healthcare Materials;2024-07-05

2. Prognostic Role of OX40, LAG-3, TIM-3 and PD-L1 Expression in Bone and Soft Tissue Sarcomas;Journal of Clinical Medicine;2024-06-20

3. Advances in drug resistance of osteosarcoma caused by pregnane X receptor;Drug Metabolism Reviews;2024-06-13

4. Exploring osteosarcoma based on the tumour microenvironment;2024-05-09

5. Circulating immunotherapy strategy based on pyroptosis and STING pathway: Mn-loaded paclitaxel prodrug nanoplatform against tumor progression and metastasis;Biomaterials;2024-04